Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 21, 2025
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
GlobeNewswire
·
May 21, 2025
Conduit regains compliance with Bid Price and Equity Requirements CDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) …
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
GlobeNewswire
·
May 21, 2025
WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
American Oncology Network Expands Access to Advanced Radioligand Therapies Across U.S. Network
GlobeNewswire
·
May 21, 2025
FORT MYERS, Fla., May 21, 2025 (GLOBE NEWSWIRE) -- American Oncology Network (AON), one of the nation’s fastest-growing community oncology networks, today announced it is expanding access to cutting-edge radioligand therapies (RLT), providing more patients …
Konica Minolta Healthcare to Launch Integrated Teleradiology Solution Powered by NewVue
GlobeNewswire
·
May 21, 2025
TAMPA, Fla. and WAYNE, N.J., May 21, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., a pioneer in imaging and healthcare IT innovation, and NewVue, the leading provider of intelligent, cloud-native radiology workflow solutions, today …
Kaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101
GlobeNewswire
·
May 21, 2025
Represents significant milestone in the development of KAD101, a novel biologic prolactin receptor antagonist, being initially developed for the treatment of platinum resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine …
Galimedix Therapeutics publishes new data in peer-reviewed International Journal of Molecular Sciences demonstrating disease-modifying capability of GAL-201 in Alzheimer’s disease
GlobeNewswire
·
May 21, 2025
Maintains Brain Connectivity: GAL-201 prevents amyloid-beta (Aβ)–induced synaptic damage by maintaining long-term potentiation, a correlate for learning and memory. Improves Memory and Behavior: Preclinical testing shows significant improvements in spatial …
The Beauty Health Company Announces Convertible Debt Refinancing
GlobeNewswire
·
May 21, 2025
LONG BEACH, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced that it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain …
Quipt Home Medical Confirms Receipt of Unsolicited Acquisition Proposal
GlobeNewswire
·
May 21, 2025
CINCINNATI, May 21, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider focused on end-to-end respiratory care, today announced that it has received an …
All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company’s Director Nominees
GlobeNewswire
·
May 21, 2025
ISS, Glass Lewis, and Egan-Jones Unanimously Conclude Mangless Has Not Made a Compelling Case for Change Board and Management Urge Stockholders to Follow Proxy Advisors’ Recommendation and Vote “FOR” Wendy L. Dixon, Ph.D. and Tamara A. Favorito on the …
Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences
GlobeNewswire
·
May 21, 2025
MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of …
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
GlobeNewswire
·
May 21, 2025
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University of North Carolina (UNC) and supported by a grant …
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 21, 2025
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company …
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
GlobeNewswire
·
May 21, 2025
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in …
GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting
GlobeNewswire
·
May 21, 2025
Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology. SAN MARINO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- GenVivo …
NeurAxis Announces $5.0 Million Registered Direct Offering
GlobeNewswire
·
May 21, 2025
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults …
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases
GlobeNewswire
·
May 21, 2025
Paris, France – May 21, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, today announces the evolution of its Scientific Advisory Board (SAB). This renewed SAB reflects Coave’s strategic shift from a platform- …
Biodesix to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 21, 2025
LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual …
EuroPCR 2025: Aktuelle Daten belegen: Die Ereignisraten nach drei Jahren sind beim DynamX® Bioadaptor von Elixir Medical anhaltend signifikant niedriger als bei medikamentenfreisetzenden Stents
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- – Anhaltende Dauerhaftigkeit des Behandlungseffekts bei signifikant niedrigeren TLF-Raten (2,7 % vs. 7,2 %, p = 0,030) bei DynamX® im Vergleich zu DES – – Signifikant niedrigere Herztodrate (0,5 % vs. 3,2 %, p = 0, …
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX® compared to DES— —Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with …
EuroPCR 2025: Los datos más recientes demuestran que el bioadaptador DynamX® de Elixir Medical ofrece tasas significativamente menores de acontecimientos adversos a lo largo de tres años en comparación con el stent liberador de fármaco
GlobeNewswire
·
May 21, 2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Durabilidad sostenida del efecto del tratamiento y tasas de fracaso de la lesión objetivo significativamente menores (2,7 % frente a 7,2 %, p=0,030) con DynamX® en comparación con SLF— —Tasa significativamente menor …